Splitting the HNSCC patients into subgroups according to the expression level of PYGL, higher IC50 of cisplatin was also observed in the PYGL-high group (Fig. 5B), and computer analysis showed a correlation with PYGL and drug resistance in the CARE database (CARE score < 0 in CCLE, CGP, CTRP respectively) (Fig. 5C), which indicated expression of PYGL was potential to induce chemotherapy resistance of cisplatin. Here, PYGL is linked to head and neck squamous cell carcinoma.